Skip to main content
Premium Trial:

Request an Annual Quote

Maxygen Posts Revenue Growth, Narrowed Loss in Q2

NEW YORK, July 30 - Maxygen today reported increases in total second-quarter  revenue and R&D spending, and a strong reduction in net loss.

 

The company said that a beefy jump in collaborative R&D revenue in the current quarter to $9.3 million from $6.0 million one year ago helped propel total receipts in the period to $10.5 million from $7.7 million over the same time last year.

 

This, plus R&D spending that in the current second quarter grew to $15.4 million from $13.0 million year over year, helped the company post a significant drop in total net loss: For the three-month period ended June 30, Maxygen said it recorded a net loss of $8.7 million, or $.26 per share, compared with $11.5 million, or $.35 per share, one year ago.

 

The Redwood City, Calif.-based company said it had roughly $221.5 million in cash, cash equivalents, and marketable securities as of June 30.

 

Click here for more information.

The Scan

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.

Study Highlights Pitfall of Large Gene Panels in Clinical Genomic Analysis

An analysis in Genetics in Medicine finds that as gene panels get larger, there is an increased chance of uncovering benign candidate variants.

Single-Cell Atlas of Drosophila Embryogenesis

A new paper in Science presents a single-cell atlas of fruit fly embryonic development over time.

Phage Cocktail Holds Promise for IBD

Researchers uncovered a combination phage therapy that targets Klebsiella pneumonia strains among individuals experiencing inflammatory bowel disease flare ups, as they report in Cell.